(Canagliflozin + teneligliptin) is a Small Molecule owned by Mitsubishi Tanabe Pharma, and is involved in 6 clinical trials, of which 5 were completed, and 1 is ongoing.
MT-2412 acts as anti diabetic agent. The combination drug candidate acts as low affinity sodium glucose cotransporter (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitor. The SGLT2 in cells lining the proximal tubule mediates the majority of renal glucose reabsorption from the tubular fluid, which normally prevents the loss of glucose in the urine. Canagliflozin by blocking SGLT2 significantly increases the amount of glucose excreted in the urine. The DPP- IV enzyme inactivates incretin hormones, which are involved in the physiologic regulation of glucose homeostasis. Teneligliptin slows the inactivation of incretin hormones and thus increases and prolongs their action which in turn increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.
The revenue for (Canagliflozin + teneligliptin) is expected to reach a total of $1.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Canagliflozin + teneligliptin) NPV Report.
(Canagliflozin + teneligliptin) is currently owned by Mitsubishi Tanabe Pharma. Daiichi Sankyo is the other company associated in development or marketing of (Canagliflozin + teneligliptin).
(Canagliflozin + teneligliptin) Overview
Canagliflozin and teneligliptin (Canalia, MT-2412) is a fixed dose combination acts as anti hyperglycemic agent. It is formulated as film coated tablets for oral route of administration. Canalia is indicated for the treatment of type 2 diabetes.
Daiichi Sankyo Overview
Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY1,044,892 million for the fiscal year ended March 2022 (FY2022), an increase of 8.6% over FY2021. In FY2022, the company’s operating margin was 7.1%, compared to an operating margin of 7% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 7.9% in FY2021.
The company reported revenues of JPY327,480 million for the second quarter ended September 2022, an increase of 16.8% over the previous quarter.
Quick View – (Canagliflozin + teneligliptin)
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Companies |
|
Highest Development Stage |
|